Daptomycin Market Research Report - Global Forecast till 2027

Global Daptomycin Market: By Indication (Complicated Skin Structure Infections, Bacteremia, others), Age Group (Pediatric, Adult), Strength (350mg, 500mg) and Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast to 2027

ID: MRFR/HC/8603-HCR | February 2021 | Region: Global | 120 pages

Please note that the assessment period of report has been updated from 2017-2027 to 2020-2027. Cordially fill the sample form for updated data.

Market Forecast


Global Daptomycin Market is expected to hold a value of USD 5,122.7 Million by 2027 and is expected to register a growth of 4.4% from 2020 to 2027.


Market Synopsis


Daptomycin is a naturally occurring lipopeptide antibiotic that kills susceptible gram-positive bacteria by disrupting their membrane potential. It is found in the soil bacterium Streptomyces rose sports. Antibiotics are used in the treatment of infections caused by bacteria. They work by killing bacteria or by preventing their growth.


Increasing complicated skin and skin structure infections, rising infections in the right bloodstream, and including right-sided infective endocarditis are the key factors that are expected to drive the market growth. Moreover, bacteremia, an antibacterial drug, a bacterial metabolite, and a member of calcium-dependent antibiotics are also expected to boost the market growth.


Market Influencer


The rise in complicated skin and skin infections lead to increased demand for daptomycin.


Market Drivers



  • High demand for daptomycin, due to rising infections in the bloodstream, including sepsis.



  • Increasing complicated skin and skin structure infections. According to the World Health Organization (WHO) report, 2018, skin diseases affected almost 900 million people in the world. Many diseases are associated with changes to the skin, from skin itching to changes in color, feel, and appearance.



  • Rise of right-sided infective endocarditis.



  • Growing role as an antibacterial drug, a bacterial metabolite, and a member of calcium-dependent antibiotics. According to the Centers for Disease Control and Prevention (CDC), the 2019 report showed that Staphylococcus aureus infections are a major problem in the US, with 1,19,000 infections and almost 20,000 deaths in 2017; thus creating a high demand of daptomycin as an antibacterial drug.


Market Restraints



  • Increasing rates of infection with gram-positive bacteria.



  • Physicians restrain their use of the new drug to avoid the rapid emergence of resistance to the new agent thereby slowing down market uptake.


Segmentation


By Indication



  • Complicated Skin Structure infections: The complicated skin structure infections segment is the fastest growing and largest segment in the market. Skin and skin structure infection is a bacterial infection of the skin and associated tissues. It often sequences treatment by antibiotics. It may be complicated skin and skin structure infection (cSSSI) or uncomplicated skin and skin structure infection.



  • Bacteremia: Bacteremia is the presence of bacteria in the bloodstream. Bacteremia may result from ordinary activities, dental or medical procedures, or from infections. The bacteria in the blood almost require treatment with antibiotics. This is because there are high mortality rates from progression to sepsis if antibiotics are delayed.



  • Others: Complicated infections include methicillin-resistant Staphylococcus aureus (MRSA) or superbug infections.


By Age Group



  • Pediatric: This segment is the fastest-growing segment. Daptomycin is well tolerated, with safety or efficiency compared to standard of care in children/ adolescents with complicated skin and skin structure infections (cSSSI) caused by gram-positive pathogens, including community-acquired methicillin-resistant Staphylococcus aureus.



  • Adult: The adult segment is the largest growing segment. Daptomycin is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.


By Strength



  • 350 mg: This segment is the fastest-growing segment. 350mg lyophilized powder used for solution for injection or infusion. This is compatible with 0.9% sodium chloride injection.



  • 500 mg: This segment is the largest growing segment. 500mg lyophilized powder used for reconstitution in a single-dose vial. This is compatible with sterile water for injection, bacteriostatic water for injection, and 0.9% sodium chloride injection.


Regional Analysis



  • Americas: Daptomycin is marketed in the US under the trade name Cubicin by Cubist Pharmaceuticals. According to Quintiles and IMS Health (IQVIA Health), Cubicin injection brand and generics had sales of around USD 606 million for 12 months ending in June 2019, which is expected to boost the market growth.



  • Europe: According to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European agency for the evaluation of Medicinal Products (EMEA), has issued a positive opinion recommending approval of an expanded Marketing Authorization for Cubicin. As per the report, the European Union (EU) and the European Economic Area (EEA) the population-weighted mean percentage of methicillin-resistant Staphylococcus aureus (MRSA) was 16.4% in 2018. The increasing cases of MRSA are expected to drive market growth.



  • Asia-Pacific: This region is amongst the highest prevalence rates of healthcare-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) and community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in the world. According to the National Center for Biotechnology Information (NCBI) report, 2018, the community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) carriage prevalence among the general public ranged from 0 to 23.5%, whereas that ranged from 0.7% to 10.4% in the hospital setting. With the rise in the number of cases of MRSA, the daptomycin market is expected to boost market growth during the forecast period.



  • The Middle East and Africa: Rise in the number of infections in the bloodstream, including sepsis is expected to drive the market. According to the African Sepsis Alliance 2017 report, 85% of sepsis cases occurred in low- or middle- income countries, especially in Sub-Saharan Africa and other regions.  The increasing number of sepsis cases is expected to drive the daptomycin market during the forecast period.


Key Players



  • Teva Pharmaceutical Industries Ltd.

  • Merck &co.

  • Cipla

  • Pfizer

  • BE Pharmaceuticals

  • Reddy’s Laboratories

  • Mylan

  • Fresenius Kabi

  • Nichi-Iko Pharmaceutical

  • Novo Holdings A/S

  • Zhejiang Hisun

  • Hengrui Medicine

  • Huadong Medicine

  • Civica Rx



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: USD 5,122.7 Million
  CAGR   4.4% (2020-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Indication, Age Group and Strength
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co (US), Cipla (India), Pfizer (US), BE Pharmaceuticals (US), Dr. Reddy’s Laboratories (India), Mylan (US), Fresenius Kabi (Germany), Nichi-Iko Pharmaceutical (Japan), Novo Holdings A/S (Denmark), Zhejiang Hisun (China), Hengrui Medicine (China), Huadong Medicine (China), Civica Rx (US).
  Key Market Opportunities   The rise in complicated skin and skin infections lead to increased demand for daptomycin.
  Key Market Drivers

  • High demand for daptomycin, due to rising infections in the bloodstream, including sepsis.
  • Increasing complicated skin and skin structure infections.
  • Rise of right-sided infective endocarditis.


  • Frequently Asked Questions (FAQ) :


    Daptomycin Market can thrive at 4.4% CAGR by 2027.

    By 2027, the Daptomycin Market value can surpass USD 5,122.7 Million.

    Fresenius Kabi, Novo Holdings A/Sare, and Nichi-Iko Pharmaceutical are some reputed Daptomycin Market players.

    Surge in cases of blood infection can drive the Daptomycin Market.

    Reluctance to used new drugs by physicians can hinder the Daptomycin Market rise.



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.